Direct effects of glucose, insulin, GLP-1, and GIP on bulbospinal neurons in the rostral ventrolateral medulla in neonatal wistar rats

Neuroscience. 2017 Mar 6:344:74-88. doi: 10.1016/j.neuroscience.2016.12.039. Epub 2017 Jan 3.

Abstract

Although patients with diabetes mellitus (DM) often exhibit hypertension, the mechanisms responsible for this correlation are not well known. We hypothesized that the bulbospinal neurons in the rostral ventrolateral medulla (RVLM) are affected by the levels of glucose, insulin, or incretins (glucagon like peptide-1 [GLP-1] or glucose-dependent insulinotropic peptide [GIP]) in patients with DM. To investigate whether RVLM neurons are activated by glucose, insulin, GLP-1, or GIP, we examined changes in the membrane potentials of bulbospinal RVLM neurons using whole-cell patch-clamp technique during superfusion with various levels of glucose or these hormones in neonatal Wistar rats. A brainstem-spinal cord preparation was used for the experiments. A low level of glucose stimulated bulbospinal RVLM neurons. During insulin superfusion, almost all the RVLM neurons were depolarized, while during GLP-1 or GIP superfusion, almost all the RVLM neurons were hyperpolarized. Next, histological examinations were performed to examine transporters for glucose and receptors for insulin, GLP-1, and GIP on RVLM neurons. Low-level glucose-depolarized RVLM neurons exhibited the presence of glucose transporter 3 (GLUT3). Meanwhile, insulin-depolarized, GLP-1-hyperpolarized, and GIP-hyperpolarized RVLM neurons showed each of the respective specific receptor. These results indicate that a low level of glucose stimulates bulbospinal RVLM neurons via specific transporters on these neurons, inducing hypertension. Furthermore, an increase in insulin or a reduction in incretins may also activate the sympathetic nervous system and induce hypertension by activating RVLM neurons via their own receptors.

Keywords: GIP; GLP-1; RVLM neurons; glucose; hypertension; insulin.

MeSH terms

  • Animals
  • Animals, Newborn
  • Central Nervous System Agents / administration & dosage
  • Gastric Inhibitory Polypeptide / metabolism*
  • Glucagon-Like Peptide 1 / metabolism*
  • Glucose / administration & dosage
  • Glucose / metabolism*
  • Glucose Transporter Type 3 / metabolism
  • Hyperinsulinism / metabolism
  • Hyperinsulinism / pathology
  • Hypoglycemia / metabolism
  • Hypoglycemia / pathology
  • Insulin / administration & dosage
  • Insulin / metabolism*
  • Medulla Oblongata / cytology
  • Medulla Oblongata / drug effects
  • Medulla Oblongata / growth & development
  • Medulla Oblongata / metabolism*
  • Membrane Potentials / drug effects
  • Membrane Potentials / physiology
  • Neurons / cytology
  • Neurons / drug effects
  • Neurons / metabolism*
  • Peptide Fragments / administration & dosage
  • Peptides / administration & dosage
  • Rats, Wistar
  • Tetrodotoxin / administration & dosage
  • Tissue Culture Techniques

Substances

  • Central Nervous System Agents
  • Glucose Transporter Type 3
  • Insulin
  • Peptide Fragments
  • Peptides
  • S961 peptide
  • Slc2a3 protein, rat
  • Tetrodotoxin
  • exendin (9-39)
  • Gastric Inhibitory Polypeptide
  • Glucagon-Like Peptide 1
  • Glucose